Understand · Treat · Recover

Hodgkin Lymphoma

Hodgkin lymphoma is often treated with the aim of cure. Modern care also tries to reduce treatment-related problems later in life.

For patients and families. This education does not replace an individual treatment plan. Do not start, stop or change medicines without the treating team.

Chapter 9 of 20 · C · Lymphoma

Confirming the type and extent

A tissue biopsy establishes the diagnosis. Classical Hodgkin lymphoma is the main group; nodular lymphocyte-predominant disease has distinct biology and may be named differently across classification systems. Treatment should follow the exact pathology. Baseline PET-CT is commonly used for classical disease, along with blood tests, symptom assessment and evaluation of heart and lung health when relevant to the planned drugs.

Early and advanced disease

Early-stage disease may be subdivided by risk factors such as bulky disease and systemic symptoms. More widespread disease does not mean cure is impossible. Fever without another explanation, drenching night sweats and significant unintentional weight loss are called B symptoms. Stage, bulk, fitness and early response help determine the length and type of treatment. A generic online survival number cannot capture those differences.

Modern first-line treatment

Chemotherapy combinations such as ABVD or AVD-based approaches remain important. AVD contains doxorubicin, vinblastine and dacarbazine; ABVD also includes bleomycin. In advanced classical disease, nivolumab with AVD is an evidence-based option, and brentuximab vedotin with AVD is another option in suitable settings. PET-adapted strategies may adjust treatment intensity or omit bleomycin after an appropriate response. Regimen choice depends on the clinical situation and local availability; families should not add, omit or substitute a medicine themselves.

Radiotherapy: benefit and late effects

Involved-site radiotherapy can help selected early-stage, bulky or residual disease situations. Modern fields aim to limit normal tissue exposure. The decision weighs relapse reduction against possible late effects on the heart, lungs, thyroid, fertility and second-cancer risk, depending on the field. A negative PET scan does not mean radiotherapy is always unnecessary; the original disease and treatment strategy still matter.

If lymphoma returns

Relapse is usually confirmed by biopsy when feasible. Options may include salvage therapy followed by autologous transplantation in suitable patients, checkpoint inhibitors such as nivolumab or pembrolizumab, and brentuximab vedotin. Some patients need other transplant strategies or trials. Choice depends on prior treatment, timing of relapse, response and organ function. A return of disease is serious, but further remission and sometimes cure remain possible.

Recovery and life after treatment

Discuss fertility preservation before treatment when feasible. Report new cough or breathlessness promptly, especially with bleomycin exposure; immune therapies can also inflame organs. Keep a treatment summary recording drug exposure and radiation fields. Long-term follow-up may include heart, lung, thyroid and risk-adapted screening checks. Persistent fatigue, anxiety or difficulty returning to work deserve support, even when scans are reassuring.

Take-home message

Cure and preservation of long-term health are both treatment goals.

Common questions

Is advanced Hodgkin lymphoma always incurable?

No. Many patients with advanced disease are treated with curative intent.

Can a residual mass be scar tissue?

Yes. Size alone does not establish active lymphoma. The team interprets PET findings, timing and sometimes a biopsy.

Sources and further reading

Cancer Aware supports patients and families worldwide. Treatment availability, approvals and care pathways vary by country; discuss local options with your healthcare team.